344 related articles for article (PubMed ID: 31152368)
1. Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C; Kotzalidis GD; Mazzarini L; Brugnoli R; Ferracuti S; De Filippis S; Cuomo I; Giordano G; Del Casale A; Angeletti G; Sani G; Girardi P
Clin Drug Investig; 2019 Aug; 39(8):713-735. PubMed ID: 31152368
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole Lauroxil: A Review in Schizophrenia.
Frampton JE
Drugs; 2017 Dec; 77(18):2049-2056. PubMed ID: 29177572
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.
Citrome L
Expert Rev Clin Pharmacol; 2016; 9(2):169-86. PubMed ID: 26573020
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
[No Abstract] [Full Text] [Related]
5. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.
Kishi T; Citrome L; Sakuma K; Iwata N
Psychiatry Res; 2024 Mar; 333():115761. PubMed ID: 38301289
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
Wang Y; Harlin M; Larsen F; Wang X; Park W; Rich B; Gobburu JV; Raoufinia A
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):631-643. PubMed ID: 38602057
[TBL] [Abstract][Full Text] [Related]
7. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
Citrome L
Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults.
Samalin L; Boudieu L; Llorca PM
Expert Rev Neurother; 2024 Mar; 24(3):291-298. PubMed ID: 38299536
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
Aggarwal A; Gopalakrishna G; Lauriello J
Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.
Keramatian K; Chakrabarty T; Yatham LN
CNS Drugs; 2019 May; 33(5):431-456. PubMed ID: 30963507
[TBL] [Abstract][Full Text] [Related]
13. A safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A; Shapiro BB
Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
[TBL] [Abstract][Full Text] [Related]
14. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
[No Abstract] [Full Text] [Related]
15. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
[TBL] [Abstract][Full Text] [Related]
18. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
Jann MW; Penzak SR
CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
[TBL] [Abstract][Full Text] [Related]
19. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
Potkin SG; Preda A
Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
[TBL] [Abstract][Full Text] [Related]
20. Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic.
Tohen M; Goldberg JF; Hassoun Y; Sureddi S
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
